78366_Auto_Edited.docx

Retrospective Cohort Study

Validation of a new index based on LDH, AST and ALT as a prognostic marker in patients with MAFLD and COVID-19.

Prognosis in MAFLD and COVID-19

Abstract

BACKGROUND

Metabolic associated fatty liver disease (MALFD) is associated with complications and mortality in patients with COVID-19. However, there are no prognostic scores aimed to evaluate the risk of severe disease specifically in patients with MAFLD, despite its high prevalence. LDH, AST and ALT have been used as markers of liver damage. Therefore, we propose an index based on LDH, AST and ALT for the prediction of complications and mortality in patients with MAFLD and COVID-19.

AIM

The Aim of this study was to evaluate the prognostic performance of an index based on LDH and transaminases (AST / ALT) in patients with COVID-19 and MAFLD (LFN-COVID-19 index).

METHODS

Retrospective cohort study, two cohorts from two different tertiary centers were included, the first was the derivation cohort to obtain the score cutoffs and the second was the validation cohort. We included hospitalized patients with severe COVID-19

and MAFLD. Liver steatosis was evaluated by CT scan. ROC curve analysis and survival analysis were used.

RESULTS

In the derivation cohort 44.6% had MAFLD; ROC analysis yielded a LFN-COVID-19 index >1.67 as the best cutoff, with a sensitivity of 78%, specificity of 63%, NPP of 91% and an AUROC 0.77. In the multivariate analysis, the LFN-COVID 19 index >1.67 was independently associated with the development acute kidney injury (OR; 1.8, CI 95%: 1.3-2.5, p< 0.001), orotracheal intubation (OR: 1.9, CI 95%: 1.4-2.4, p< 0.001), and death (OR: 2.86, CI 95%: 1.6-4.5, p< 0.001) in both cohorts.

CONCLUSION

LFN-COVID-19 index has a good performance to predict prognosis in patients with MAFLD and COVID-19 which could be useful for the MAFLD population.

Key Words: COVID-19; Metabolic Associated Fatty Liver Disease; Lactate dehydrogenase; transaminases; Prognosis; NAFLD

Macías-Rodríguez RU, Solís-Ortega AA, Ornelas-Arroyo VJ, Ruiz-Margáin A, González-Huezo MS, Urdiales-Morán NA, Román-Calleja BM, Mayorquín-Aguilar JM, González-Regueiro JA, Campos-Murguía A, Toledo-Coronado IV, Chapa-Ibargüengoitia M, Valencia-Peña B, Martínez-Cabrera CF, Flores-García NC. Validation of a new index based on LDH, AST and ALT as a prognostic marker in patients with MAFLD and COVID-19.. *World J Gastroenterol* 2022; In press

Core Tip: The LFN-COVID-19 index is a new prognostic index, that includes serum LDH, AST and ALT levels, developed to specifically predict adverse clinical outcomes including mortality, in patients with metabolic-associated fatty liver disease and COVID-19. The variables included in this index, allow an easy, quick and reliable risk

assessment in this population with simple markers, allowing for broad implementation.

INTRODUCTION

The SARS-CoV-2 pandemic (COVID-19) still affects the entire world, having as of June 15, 2022, 536,720,870 people infected, of whom 6,312,601 have died(1).

Different risk factors associated with the development of complications and mortality in patients with COVID-19 have been identified, including age >60 years, the presence of cirrhosis, diabetes, immunodeficiencies, obesity, cardiovascular disease, chronic kidney disease, chronic obstructive pulmonary disease, among others(2–4). Metabolic dysfunction associated fatty liver disease (MAFLD), regarded as the hepatic manifestation of metabolic syndrome, has a controversial role in the prognosis of patients with COVID-19. Some studies have reported a poor prognosis in patients with MAFLD, while others have only showed this finding when fibrosis is present. This could be explained by a more pronounced baseline systemic inflammatory profile and activation of the immune response in patients with liver fibrosis, which contributes to increased inflammation when SARS-CoV-2 infection is added(5,6).

Acute respiratory distress syndrome (ARDS) is the major complication in patients with severe COVID-19; other complications such as cardiac or cardiovascular, renal, and secondary infections, among others, may occur.(7) These patients, mainly those admitted to the intensive care unit, may present with laboratory abnormalities, such as leukopenia, lymphopenia (<800 mm^3 at admission), elevated prothrombin time, elevated serum levels of D-dimer (> 1000 ng/mL), elevated inflammatory markers (ferritin >300 ug/L), elevated lactate dehydrogenase (LDH), elevated liver enzymes, elevated creatine phosphokinase (CPK twice the upper limit of normal), and elevated troponin I (hs-TpI) (7–9).

In patients with pneumonia associated with SARS-CoV-2 infection, high LDH levels correlate with lung damage, severe disease and mortality at day 30. (10–13) In the study by Yan L *et al* LDH (>365 U/L), lymphocyte count (<14.7%) and CRP (>41.2 mg/L) were identified as the three laboratory abnormalities that predict mortality risk with 90% accuracy, which represent a simple way to promptly recognize severe illness.(14)

Likewise, in patients with acute liver injury (non-COVID-19 related), an increase in LDH levels has been reported, secondary to endothelial damage induced by macrophages during acute inflammation, conditioning microcirculation alterations and hypoxia. Thus, it has been suggested that LDH may have a discriminatory role in identifying the etiology of liver damage. As a marker of damage due to liver ischemia, it must be taken into account that LDH has a shorter half-life, therefore a faster fall when the damage disappears, so it has been suggested as a parameter to monitor the evolution of patients with acute liver injury. The ubiquitous nature of LHD in the human body makes it a nonspecific but sensitive biomarker, which in the context of organ damage can provide information with diagnostic and prognostic potential. In the same way, increase in ALT, AST and the AST/ALT ratio has been associated to adverse clinical outcomes including mortality in patients with COVID-19. (10–13,15)

Identifying factors associated with poor prognosis that may be related to a pathophysiological mechanism is ideal in patients with COVID-19, since those patients at risk of progressing to a severe illness could be identified promptly, so measures can be taken to influence the outcomes of those patients. In this sense, having a prognostic index specific for patients with MAFLD who develop COVID-19, may be useful to identify individuals at risk of developing adverse clinical outcomes.
Therefore, the aim of this study was to evaluate the performance of a prognostic index based on LDH, AST and ALT in patients with MAFLD and COVID-19 and its association with the development of adverse clinical outcomes and mortality.

MATERIALS AND METHODS

This was a retrospective cohort study performed at two third-level hospitals in Mexico, (INCMNSZ and ISSEMyM) from march to July 2020, during the first phase of the COVID-19 pandemic, and before steroids became a standard of care for severe COVID-19. The study was carried out according to Declaration of Helsinki and was approved by the institutional Ethics Committee (Ref. No. 3777).

Validation process

This study consisted of two phases:

Phase 1 Derivation or training cohort: The methods described below were used to create and evaluate the newly proposed prognostic index. This cohort was derived from a tertiary care center hospital in Mexico City (INCMNSZ).

Phase 2 Validation cohort: This aimed to evaluate the diagnostic performance of the proposed index also in patients with COVID-19 and liver steatosis in a different center. This cohort was derived from a tertiary care center hospital in Toluca, in the center of Mexico (ISSEMYM).

Patients

All patients admitted during the period of study, >18 years of age, any gender, and with a confirmed diagnosis of SARS-CoV-2 infection by RT-PCR and with severe disease (pneumonia + respiratory rate >30/respiratory distress/ SaO2 < 90%) , were included in the study(19). Patients without an adequate follow up were excluded from the analysis (v.gr. those requiring referral to other hospital, with insufficient information in the clinical records, *etc.*). Follow up and evaluation of the clinical outcomes was conducted through revision of electronic clinical records.

Biochemical tests

Upon admission, a blood sample was drawn for determination of the following tests: complete blood count, glucose, creatinine, electrolytes, ferritin, C reactive protein, LDH,

liver chemistry, CPK, arterial blood gases, D dimer, hs-TpI and fibrinogen. HIV and viral hepatitis panel (HCV and HBV) was performed in all the participants. All the tests met the quality standards from our central laboratory, accredited by the College of American Pathologists (CAP).

CT scan

In order to evaluate the severity of pulmonary involvement, all patients underwent a pulmonary CT scan, where a portion of the liver was also evaluated for the presence of steatosis. The methodology was previously described from our group (16). Briefly, an expert radiologist blinded to patient´s clinical status evaluated CT scans to detect liver steatosis, according to the following criteria: (a) attenuation coefficient ≤40 Hounsfield units (HU) in the liver (segments VII and VIII); and b) attenuation coefficient ≥10 HU between the splenic and liver parenchyma.

Estimation of the LFN-COVID-19 Index

The Liver Fibrosis and Nutrition lab (LFN) COVID-19 index was calculated according to the following formula:

Where AST/ALT ratio included transaminase levels expressed in U/L and was multiplied by the times above the upper limit of normal value for LDH (U/L). Final value was included in the statistical analysis for characterization of clinical outcomes.

Statistical analysis

Sample size estimation considered a hypothetical area under receiver operating characteristic curve (AUROC) of 0.8 for LFN-COVID-19 index, and 0.7 as null hypothesis. Considering an alpha error of 0.05 and beta 0.20, and a negative/positive ratio of 1/1, estimation yielded 81 negative/positive cases (162 patients in total).

Normality of the data was evaluated with Kolmogorov-Smirnov test. Data is presented as mean ± SD, median (P25-P75) or absolute frequencies. Comparisons between the groups were made through Mann-Whitney U or Student´s t-test. ROC curve analysis was performed to obtain the best cutoff from LFN-COVID-19 index for mortality, through Youden index, as well as sensitivity, specificity, positive and negative predictive values, and likelihood ratio.

Clinical outcomes were evaluated by logistic regression, and a time-dependent survival analysis, including Kaplan-Meier and Cox-regression (Cox proportional-hazards model) for 28-day mortality and general mortality. Statistical analysis was carried out with the statistics software SPSS version 20.0 (IBM, Armonk, NY, EE. UU.) and ROC analysis with MedCalc Statistical Software version 19.4.1 (MedCalc Software Ltd, Ostend, Belgium).

RESULTS

In validation cohort a total of 457 patients were included in the final analysis (figure 1), after excluding those without an adequate follow up, CT scan (artifacts, unable to evaluate liver or spleen tissue, post-surgical changes) or those with known autoimmune liver diseases, HIV, hepatitis C or B chronic infection or cancer.

Participant's characteristics:

General characteristics of study population, with and without MAFLD are presented in Table 1. Mean age in total population was 50.4 ± 13.3 years, most of the patients were male (65.2%) and the mean BMI was 30.1 ± 5.6 kg/m^2. In general, in the group of patients with MAFLD there was higher prevalence of overweight and obesity, were younger than those without MAFLD, and had higher prevalence of diabetes and metabolic syndrome.

Biochemical tests:

Biochemical tests related to proinflammatory status, such as LDH, CPK, lymphocytes and neutrophils/Lymphocytes ratio, were higher in the MAFLD group, as well as liver chemistry abnormalities, glucose, triglycerides and prognostic scores (SOFA).

Index diagnostic performance:

In the group of patients with MAFLD, diagnostic yield of the LFN-COVID-19 index ([AST/ALT]*[DHL/DHL$_{ULN}$]) was investigated, through area under the ROC curve (AUROC) analysis, to determine the prognostic value of the index as a prognostic marker in patients with COVID-19. Characteristics related to diagnostic yield of the LFN-COVID-19 index are shown in table 2. According to Youden´s index, the best cut off value of the LFN-COVID-19 index for mortality, in patients with MAFLD was >1.67. This cut off value showed an AUROC of 0.77 (CI 95% 0.709 - 0.823, p <0.0001), with a sensitivity of 78.7% and specificity 63.8% (Figure 2a). In general, AUROC in this group of patients was better than in patients without MAFLD (AUROC 0.703, CI 95% 0.647 - 0.755, p<0.0001) (Figure 2b).

Table 3 shows the characteristics of patients with MAFLD according to the LFN-COVID-19 index. Similitudes in both groups regarding metabolic syndrome and BMI were observed, while other variables including age, prognostic scores, and biomarkers related to proinflammatory and prothrombotic status, severe COVID-19 (PaO$_2$/FiO$_2$ <100mmHg), orotracheal intubation and other clinical outcomes, including mortality, were higher in the >1.67 group.

Prognostic performance:

In order to determine if the LFN-COVID-19 index is independently associated with the presence of acute kidney injury or orotracheal intubation during hospitalization, a logistic regression was performed, observing that a value of >1.67 is associated to adverse clinical outcomes, independently of metabolic factors, severity scores and demographic variables. (Table 4).

As a marker of mortality was studied by a 28-day Kaplan-Meier survival analysis (Figure 3), observing that patients with a value >1.67, have a lower survival than those with a value <1.67 (p<0.001). The influence of other variables on mortality was evaluated through uni- and multivariate Cox proportional-hazards analysis, in table 5 are summarized the variables that were significant in the univariate analysis, with the results when subjected to the multivariate analysis where the variables that were independently associated with mortality were the LFN-COVID-19 index, the Neutrophil/Lymphocyte ratio and the BMI.

In this analysis, a LFN-COVID-19 index >1.67 was associated independently to other variables to mortality, including severity markers, prognostic scores and general characteristics (Figure 4).

Validation cohort

From the 697 patients included in the validation cohort, 104 had MAFLD (15.0%). In general, patients with MAFLD were younger, had higher degrees of obesity and mild abnormalities in liver chemistry (Supplementary table 1). The MAFLD group was further analyzed according to the LFN-COVID-19 index, finding higher levels of CRP and D-dimer in the group >1.67, with little changes in the rest of the variables (Supplementary table 2). Interestingly, mechanical intubation and clinical outcomes including mortality, were more frequent in the >1.67 group, as was found in the initial cohort (Supplementary table 3). These same findings, in another cohort and in a different hospital, highlights the validity of the LFN-COVID-19 index.

DISCUSSION

Metabolic dysfunction-associated fatty liver disease (MAFLD) is currently the main etiology of chronic liver disease in the world. The main associated risk factors are obesity, type 2 diabetes, dyslipidemia and metabolic syndrome, factors with a growing incidence. Both risk factors for MAFLD and MAFLD itself, have also been shown to

have prognostic value in COVID-19, associating their presence with higher severity and mortality. However, it remains controversial whether all patients within the spectrum of MAFLD have a worse prognosis or only those who, in addition to steatosis, have fibrosis. (16)

Evidence pointing to MAFLD as a prognostic factor emerges from different studies around the world. A retrospective study in patients with COVID-19, found an association of MAFLD with higher ICU admittance (OR 2.3 CI 95% 1.27-4.17), mechanical ventilation (2.08 CI 95% 1.2-3.6) and in patients with cirrhosis with higher mortality (12.5 CI 95% 2.16-72.5). (6)In a cohort study in patients with COVID-19 and chronic liver disease (42% MAFLD) observed a RR of 2.8 (95%CI 1.9-4.0) for death in these group of patients, regardless of age, race, BMI, presence of hypertension or diabetes.(12) Another study conducted in Zhejiang, China found that hospitalized COVID-19 patients who had MAFLD with fibrosis (evaluated through FIB-4 and NFS scores) were at increased risk of severe disease, regardless of other comorbidities. (5) Lastly, a study conducted by Dong Ji *et al* showed that patient with COVID-19 and MAFLD had a higher prevalence of alterations in liver biochemistry test as well as a longer viral clearance time compared with patients without MAFLD.(17)

Considering the evidence mentioned above, it is possible that the synergism between the baseline proinflammatory state of patients with MAFLD together with the body´s inflammatory response to COVID-19 could be the pathophysiological support that explains greater severity and worse prognosis in these patients. Another important component in multiorgan damage in COVID-19, is the state of hypoxemia, cell death and hypoperfusion reflected by biomarkers such as LDH, which correlates positively with worse clinical outcomes (including mortality), and although it is not specific for liver damage, it can be a sensitive and dynamic marker of hypoxic tissue damage due to its short half-life, together with other well-known markers of liver damage, as AST, ALT and the AST/ALT ratio. (10)

Due to the link between MAFLD and COVID-19, and the higher risk of mortality and adverse clinical outcomes, we conceived a prognostic index intended to be used in patients with MAFLD, including variables reflecting somehow the pathophysiology of liver damage, mainly hepatocyte cell death induced by the factors previously mentioned, and associating it with hard clinical outcomes, including mortality (18). The LFN-COVID-19 index, includes the AST/ALT ratio as well as LDH levels normalized by laboratory´s upper limit of normal, facilitating the implementation of the index by non-restricting its usefulness to a specific cutoff value (AST, ALT or LDH), and therefore overcoming the problem of regional variations in laboratory values. The use of this index has potential implications in clinical practice establishing a prognosis of patients, on the other hand the simplicity of the index allows to calculate it without complex calculators, and includes widely available, cheap and reliably laboratory tests.

In the present study, we found a good diagnostic performance of the LFN-COVID-19 index in hospitalized patients with MAFLD and COVID-19. In the ROC curve analysis, a cutoff value of >1.67 was associated with adverse clinical outcomes including need for mechanical ventilation, acute kidney injury and higher mortality. This was reproduced in the validation cohort performed at a different center finding this cut-off point as the best for predicting these outcomes.

An interesting finding was that there were no differences in the days of stay in the ICU based on this cut-off point. The same length of stay in the ICU could be explained by the severity of the disease, where those with an index below 1.67 were discharged from the critical care area earlier and those with an index above 1.67, present earlier mortality.

Among the weaknesses of this study is the fact that the diagnosis of hepatic steatosis was made with computed tomography, however, given the high risk of transmission of SARS-CoV-2 to healthcare workers, this safer approach was chosen in order to reduce

the exposure involved in carrying out a study such as transient hepatic elastography or MRI requiring more time to perform it. Another aspect to highlight is that patients with COVID-19 usually present elevated transaminases and LDH of multifactorial cause. Nevertheless, both biomarkers have been widely used as markers of hepatocyte cell death, and may reflect liver damage occurring during SARS-CoV-2 infection, and exacerbated in patients with MAFLD.

This study has several strengths too: sample size, the fact that it was carried out in a center fully converted for the care of COVID-19 patients, which included the general population, in a country with one of the highest prevalence of MAFLD and a genetic profile that predisposes to the development of metabolic diseases such as T2DM, obesity and metabolic syndrome. On the other hand, we included an external validation cohort, where the results were replicated, enhancing the validity of the LFN-COVID-19 index.

CONCLUSION

Finally, based on the findings of this study, we propose a new prognostic index based on markers of liver damage and severity in patients with MAFLD and COVID-19, which can be used in clinical practice to stratify the risk of adverse outcomes in MAFLD patients, and timely set actions to reduce the associated morbidity and mortality in this population.

ARTICLE HIGHLIGHTS

Research background

This article was conceived considering the high prevalence of metabolic-associated fatty liver disease in the general population, amid the COVID-19 pandemic, and therefore the risk of facing patients with both conditions, in some clinical settings with limited resources.

Research motivation

The growing evidence showing worse clinical outcomes in patients with metabolic diseases and COVID-19, including those with fatty liver disease, and the lack of a specific index, allowing to specifically risk-stratify patients with both conditions, motivated the creation of an index capable of discriminating those patients with an unfavorable outcome.

Research objectives

To Evaluate the diagnostic yield of the LFN-COVID-19 index (it includes LDH, AST and ALT values), to predict adverse clinical outcomes, including mortality, in patients with both COVID-19 and metabolic associated fatty liver disease (MAFLD).

Research methods

Data from a derivation cohort, including patients admitted with a diagnosis of severe COVID-19 and meeting the MAFLD criteria, allowed to identify the best LFN-COVID-19 index cutoff value for risk stratification. The results were evaluated using a validation cohort.

Research results

The liver fibrosis and nutrition lab (LFN)-COVID-19 index with a cut-off point >1.67 was associated with higher mortality ($p<0.001$) with an area under the curve of 0.77 (95%CI 0.709-0.823), sensitivity: 78.7% , specificity: 63.8% and it was independently associated with worse outcomes such as higher mortality, intubation rate and acute kidney injury, in both cohorts.

Research conclusions

The LFN-COVID-19 index with a cut-off point >1.67 showed good discrimination capability in patients with severe COVID-19 and MAFLD, identifying patients with an

unfavorable prognosis associated with the need for mechanical ventilation, acute kidney injury and higher mortality.

Research perspectives

The use of this prognostic index, will allow timely identification of patients with MAFLD and COVID-19 at higher risk of adverse clinical outcomes, leading to better therapeutic decision-making and resource allocation.

78366_Auto_Edited.docx

ORIGINALITY REPORT

3%

SIMILARITY INDEX

PRIMARY SOURCES

1 Alejandro Campos-Murguía, Berenice Monserrat Román-Calleja, Israel Vicente Toledo-Coronado, José Alberto González-Regueiro et al. "LIVER FIBROSIS IN PATIENTS WITH METABOLIC ASSOCIATED FATTY LIVER DISEASE IS A RISK FACTOR FOR ADVERSE OUTCOMES IN COVID-19", Digestive and Liver Disease, 2021
Crossref

55 words — 1%

2 www.ncbi.nlm.nih.gov
Internet

27 words — 1%

3 Maribel Botana-Rial, Lorena Vázquez-Iglesias, Pedro Casado-Rey, María Páez de la Cadena et al. "Validation of Calprotectin As a Novel Biomarker For The Diagnosis of Pleural Effusion: a Multicentre Trial", Scientific Reports, 2020
Crossref

14 words — < 1%

4 id.nii.ac.jp
Internet

14 words — < 1%

5 www.xiahepublishing.com
Internet

13 words — < 1%

EXCLUDE QUOTES	ON	EXCLUDE SOURCES	< 12 WORDS
EXCLUDE BIBLIOGRAPHY	ON	EXCLUDE MATCHES	< 12 WORDS